BioSpace News Archive

Indianapolis facility to support full range of reusable Crēdo™ offerings

Lenzie to expand company’s manufacturing capabilities to meet increasing customer demand

Common stock and warrants were sold together in fixed combination at $1.20 per unit, totaling approximately $20 million in gross proceeds

Ms. Wood will co-lead the firm’s Food, Drug and Medical Device Regulatory practice and the D.C. office FDA group

Firm Ranked Top 10 in Each Award Category

Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy

Akero’s lead program AKR-001 to advance into Phase 2 clinical studies in 2019

Hearthside Home Care awarded FirstLight Home Care franchise, becomes first conversion in franchise system

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today (1) that it has received the decision of the Nasdaq Hearings Panel (the “Panel”) to grant it a extension until October 15, 2018

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the “Options”) on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director.